Atmobiosciences
1 known investors
Atmo Biosciences develops an ingestible capsule system that measures gastrointestinal tract transit times and motility using gas sensors and wireless data transmission to diagnose functional gut disorders like gastroparesis and slow transit constipation. The system targets healthcare providers and patients managing chronic gastrointestinal motility disorders.